The role of complement immune response on artemisinin-based combination therapy in a population from malaria endemic region of Western Kenya

Background Naturally acquired immunity (NAI), which is characterized by protection against overt clinical disease and high parasitaemia, is acquired with age and transmission intensity. The role of NAI on the efficacy of anti-malarial drugs, including artemisinin-based combinations used as the first-line treatment for uncomplicated Plasmodium falciparum, has not been fully demonstrated. This study investigated the role of NAI in response to artemisinin-based combination therapy (ACT), in symptomatic patients living in western Kenya, a high malaria transmission area. Methods Sera samples from malaria immune participants (n = 105) in a therapeutic efficacy study were assessed for in vitro growth inhibitory activity against the 3D7 strain of P. falciparum using a fluorescent-based growth inhibition assay (GIA). Participants’ age and parasite clearance parameters were used in the analysis. Pooled sera from malaria naïve participants (n = 6) with no Plasmodium infection from malaria non-endemic regions of Kenya was used as negative control. Results The key observations of the study were as follows: (1) Sera with intact complement displayed higher GIA activity at lower (1%) serum dilutions (p < 0.0001); (2) there was significant relationship between GIA activity, parasite clearance rate (p = 0.05) and slope half-life (p = 0.025); and (3) age was a confounding factor when comparing the GIA activity with parasite clearance kinetics. Conclusion This study demonstrates for the first time there is synergy of complement, pre-existing immunity, and drug treatment in younger patients with symptomatic malaria in a high-transmission area.

Naturally acquired immunity has been shown to influence malaria drug treatment outcomes by enhancing the efficacy of sub-optimal drug regimen and delaying the emergence of drug resistance, including the artemisininbased combinations used as the first-line treatment of Plasmodium falciparum in most malaria endemic countries [4]. Artemisinin-based combination therapy (ACT) is still highly efficacious in sub-Saharan Africa (sSA) [5], but as malaria transmission reduces, and malaria immunity at population level wanes [6], the efficacy of ACT is likely to be impacted. It is, therefore, important to monitor and assess the effect of pre-existing acquired immunity on the efficacy of ACT as part of therapeutic efficacy studies (TESs).
Complement factors have been shown to play a key role in antibody-mediated immunity to malaria in humans [7]. Studies from malaria endemic areas have demonstrated that P. falciparum exposure is associated with growth-inhibitory activity in total [8], and merozoite surface protein 1 (MSP-1) or apical membrane antigen 1 (AMA-1)-specific IgG fractions [9,10]. Growth inhibition assays (GIA) assesses the functional activity of sera to reduce/inhibit red blood cell (RBC) invasion and/or intra-RBC growth of P. falciparum in vitro [11]. Using GIA, the present study aimed to assess the role of complement and pre-existing immunity in the response to malaria drug treatment in symptomatic patients living in a malaria high-transmission area of western Kenya.

Study site, population and sample collection
This is a sub-study that analysed samples from a TES conducted in Kombewa district hospital in Kisumu County, western Kenya from June 2013 through November 2014. Detailed clinical study will be reported elsewhere. Briefly, Kisumu County is a malaria holoendemic lake region with intense malaria transmission through-out the year, with annual entomological inoculation rates (EIR) of 31.1 infected bite per year [12]. This was a two-arm, randomized open-label study, where patients presenting with uncomplicated malaria at the Kombewa district hospital between the ages of 6 months to 65 years were recruited (Table 1). Study participants were randomized to receive artemether-lumefantrine (AL) or artesunate-mefloquine (ASMQ) using block randomization schemes with varying block sizes. Venous blood samples were collected at hours 0, 4, 8, 12, 18, 24 and then every 6 h until two consecutive smears became negative. Giemsa-stained films were prepared following World Health Organization (WHO) guidance and read by two independent expert microscopists. The geometric mean of the parasite count per microlitre from each participant at each sampling time point was then calculated. Participants were followed for a total of 42 days. A total of 118 participants were enrolled in the study, 59 from each arm. From these, 105 blood samples from study participants (46 participants who were < 5 years of age and 59 who were ≥ 5 years of age) herein regarded as immune sera sample were successfully analysed using the GIA.
Pooled sera from six adult males 18-65 years old, who were P. falciparum negative, confirmed by microscopy and polymerase chain reaction (PCR), were used as non-immune control for the GIA experiments. These donors had blood groups A, B and O, and haemoglobin level of ≥ 13 g/dL, living in malaria non-endemic regions (Kericho and Nairobi), with no travel history to malaria endemic areas of Kenya in the last 6 months prior to blood donation. For the maintenance of the parasite culture and performing the GIA assays, red blood cells (RBCs) were obtained from blood group "O" donors, ages between 18 and 50 years, with haemoglobin level of 14-18 g/dL for males, and 12-16 g/dL for females living in a malaria non-endemic area (Kericho and Nairobi) with no travel history to malaria endemic areas in the last 6 months prior to donating blood. After collection, the blood was kept in cool boxes containing 2-8 °C ice parks with portable thermometers, which were safely transported to the central lab by courier service provider under monitored cold chain within 24 h. The cold chain, and sample integrity including absence of lysis and leakage was verified by the receiving technician and documented in the laboratory record book prior to processing as previously described [13]. Briefly, in 15 mL centrifuge tubes, 7 mL aliquots of the whole blood were added to 7 mL wash medium and then centrifuged at 800g for 10 min where most white blood cells (WBCs) in buffy coat were gently aspirated, followed by the entire supernatant, leaving the packed RBCs. The process was repeated three-time to remove all the remaining WBCs. The cells were then suspended in equivalent wash medium at 50% haematocrit (packed cells/wash medium v/v), then stored at 2-8 °C.

Culture media
Culture medium used to maintain P. falciparum in vitro (Life technologies, Carlsbad, CA) was prepared as previously described [14].

Plasmodium falciparum culture
Plasmodium falciparum 3D7 strain, obtained through Biodefense and Emerging Infections Research Resources Repository (BEI Resources, NIAID, NIH) was maintained in continuous culture as previously described [13]. Briefly, P. falciparum-3D7 were suspended in 5 mL of complete media with serum (CMS) at 6% haematocrit in tissue culture flasks (Corning Glass Works, Corning, NY). The flasks were flushed with a gas mixture consisting of 5% oxygen, 5% carbon (IV) oxide and 90% nitrogen (Air Products Corp., Allentown, PA), sealed, and incubated at 37 °C. The medium was changed daily, and fresh RBCs added when required. Parasite growth was monitored microscopically by counting Giemsa-stained thin blood smears. When parasitaemia exceeded 3%, ring-stage parasites were synchronized by sorbitol lysis (5% d-sorbitol (Sigma, St. Louis, MO) as follows: Parasites were mixed and transferred into a 15 mL centrifuge tube and centrifuged at 800 g for 10 min. After removing the supernatant, 5% d-sorbitol pre-warmed to 37 °C was added to the RBC pellet, incubated for 10 min at 37 °C, vortexed for 1 min and re-centrifuged at 800 g for 10 min. After aspirating the supernatant and repeating the process twice using TCM, ≥ 90% ring forms was achieved.

Serum preparation
Serum was obtained from blood samples as previously described [15] with minor modifications. Briefly, whole blood collected in plain (anticoagulant free) blood bags from each study participant was stored at 2-8 °C overnight to allow settling of the serum and cells portions. Serum portion was transferred into 50 mL centrifuge tubes, and centrifuged at 800 g for 10 min. The supernatant was transferred into 50 mL centrifuge tube to remove all cell components. This step was repeated three times, and the serum was stored at -65 to -80 °C until further use. The sera from the six male adults (non-immune) was pooled together forming approximately 2000 mL, which was used as negative control for subsequent experiments. Serum from each of the immune or non-immune pooled serum was divided into two equal portions. One portion was heat inactivated at 56 °C for 30 min in a water bath, as previously described [7]. Experiments were carried out in 1 or 10% sera, prepared as previously described [7]. Briefly, 10% immune or non-immune CMS was prepared by adding 0.5 mL participant's serum to 4.5 mL serum free media. To prepare 1% immune or non-immune CMS, 0.5 mL of 10% immune/non-immune CMS was added to 4.5 mL serum free media, making a tenfold dilution. This was done for heat-inactivated and non-heat inactivated sera.

Growth inhibition assay (GIA)
In vitro anti-plasmodial susceptibility assay was performed as previously described [14] with some modifications. Briefly, tenfold dilution in TCM was done for immune serum, non-immune serum, and negative control wells. Parasitaemia in the GIA assays of continuous culture that were greater than 3% were lowered to 1%, and adjusted to final 1-2% hematocrit. Parasite replication was quantified for each serum sample (immune/pooled non-immune sera) and expressed as the mean percentage growth inhibition by: Optimization was done to validate the assay and control reference ranges were established upon which the assay performance was monitored using anti-malarial drugs dihydroartemisinin (DHA) and lumefantrine (LU) that have known IC 50 for the reference parasite strain. The drugs DHA and LU were used as positive control and tissue culture media (10% CMS) was used as negative control. All experiments were conducted in triplicate.

Parasite clearance rates calculation
The statistical models used to estimate the parasite clearance measures and lag phase duration were fitted using the Parasite Clearance Estimator (PCE) tool developed by Worldwide Antimalarial Resistance Network (WWARN) [17]. Briefly, thick and thin smears of malaria blood slides were generated examined under light microscope at 100× magnification for presence of malaria parasites as part of monitoring treatment outcome. From the initial scan through slides with parasite counts/WBC count ratio less than 2 in thick smears were regarded as low density infection and reading done in this smear. The parasite density in this low density smears were estimated as the number of parasites, the asexual forms only, counted against the number of white blood cells (usually 200 for low density or 500 for extra low density with less than 10 parasites pre 200 WBCs). Slides with parasite counts/WBC count ratio exceeding two were counted in thin smear as infected RBC counts/total number of RBC Data was downloaded from the PCE and the following parameters were estimated: parasite clearance half-life, parasite clearance rate constant (K/h), and the estimated time to reduce parasitaemia by 50% (PC50), 90% (PC90), 95% (PC95), and 99% (PC99). Log transformed parasite density was plotted against time in hours to generate slope half-life (T 1/2 ) which is defined as the time needed for parasitaemia to be reduced by half [18]. This constant is independent of starting value of parasitaemia. The slope half-life was calculated as follows:T 1/2 = log e (2)/K = 0.692/K, where K is the clearance rate constant. The clearance rate K represents the rate of parasite clearance after start of drug treatment.

Statistical analysis
Data was analysed using GraphPad Prism version 5.03 (GraphPad software, Inc., San Diego, CA) and Minitab, Version 17 (Minitab Inc., State College, PA). Normality of the data was confirmed using Shapiro-Wilk test. Data are presented as the median with interquartile range ([IQR] 25th and 75th percentiles). Statistical difference between groups was determined using t test and Wilcoxon matched-pairs signed rank test. Correlation between groups was assessed using Pearson correlation coefficient test. Differences with a p-value less than 0.05 were considered statistically significant.

Growth inhibitory activity
The in vitro growth inhibition of P. falciparum in serum from the 105 immune study participants and nonimmune were compared using Wilcoxon matched pair signed rank test. The percentage growth inhibition of P. falciparum at 10 and 1% serum concentration from the study participants was significantly higher than for the non-immune controls (p < 0.0001) (Fig. 1), indicating parasite growth inhibition was due to the immune status. There was no statistically significant difference in percentage growth inhibition for heat inactivated (+HA) serum compared to non-heat inactivated (−HA) serum at 10% serum concentration (p = 0.18). Conversely, the percentage growth inhibition was significantly higher for −HA serum than +HA serum at 1% serum concentration (p = 0.009) (Fig. 2). The results revealed the role of complement when the assay was performed at 1% serum concentrations where antibodies are at limiting concentrations.

Age and GIA activity
To determine whether age or parasitaemia were confounding factors in GIA, the GIA data were stratified based on individuals younger than 5 years (< 5 years) or 5 years and older (≥ 5 years). There was no age-dependence of GIA activity nor significant correlation between GIA activity and parasite density (R 2 = 0.03, p = 0.95 Pearson correlation coefficient) (Fig. 3).

Impact of pre-existing immunity, GIA and treatment outcome
The main question of the present study was whether pre-existing immunity had an impact on the parasitological outcome after drug treatment and the kinetic of the response. The mean T 1/2 for both study arms combined was 2.38 h (95% confidence interval [CI], 2.23-2.52), the median was 2.40 h (interquartile range [IQR], 1.95-2.80), and the range was 0.97-4.22 h. The cutoff values for stratifying into the two different groups have previously been described [19,20]. Correlations between drug treatment outcome as determined by parasite clearance parameters (slope half-life [T 1/2 ] and clearance rate [K]) and pre-existing GIA activity in sera were assessed ( Table 2). The main observation when performing the statistical analyses was that stratifying the data based on the kinetic of the drug response revealed two factors, complement and age were associated with a faster parasite clearance and slope halflife. Non-heat inactivated sera from study participants younger than 5 years showed a significant negative correlation between GIA activity and slope half-life (R 2 = 0.698, p = 0.025 Pearson correlation) and a significant positive correlation between GIA activity and parasite clearance (R 2 = 0.604, p = 0.05 Pearson correlation). These correlations are lost when sera were heat-inactivated, clearly demonstrating the role of complement in clearing the parasite under drug treatment.

Discussion
The present study utilized samples from a TES study with a comprehensive immunological profile [20] and parasitological characterization. To complete the immuneparasitological profile, the functional activity of sera Fig. 1 Anti-parasite activity in sera from study participants reaches saturation at a low testing concentration. Individual data plot represents in vitro growth inhibition of P. falciparum parasites (3D7) in the presence of 10% or 1% (v/v) serum concentration from immune patients. Circles indicate results for each study participant (n = 105). A serum pool consistent of six non-immune volunteers (indicated by blue line) was tested to determine background activity of the GIA assay. Median and 95% confidence interval are indicated for each experimental conditions Fig. 2 The contribution of complement to anti-parasite activity in sera is revealed at lower concentrations. Boxplot comparing GIA activity of Sera tested at 1% (left panel) (n = 105) and 10% (right panel) n = 105) with (+HA) and without (−HA) complement inactivation collected prior to drug treatment was assessed in a sensitive GIA assay [14]. To determine the contribution of innate factors such as complement, sera were tested with and without heat-inactivation. The initial analysis showed that the contribution of complement to the anti-parasite activity was only notable at low serum concentrations, where anti-malarial antibodies are likely under limiting concentrations. This confirms previous reports demonstrating the role of complement in GIA activity [7,20]. The next step was to determine the impact of age on the GIA activity. Contrarily to a previous study [21], an age-dependent response in the functional activity was not displayed by the sera. This contradiction is likely because in the current study, population is comprised of participants that presented with malaria symptoms while other studies investigated the role of age in asymptomatic populations.
The key observation of this study was made when the data were stratified based on the drug kinetic response of the study participants [20]. This classification revealed that the parasitological response (i.e., parasite clearance rate and slope half-life) to drug was linked to GIA activity in non-heat-inactivated sera in patients under the age of five (Table 2). This finding suggests that the role of complement varies depending on the age of the study participant, corroborating previous studies that have demonstrated the importance of age in immune acquisition [22][23][24]. Previous assessment of the serological antibody profile did not find differences between the age groups [20] and, therefore, findings in this study points towards a greater role of innate factors in younger patients. The need for complement and complement fixing antibodies has been reported to be crucial for the protection against malaria clinical disease [7], supporting observation in this study that heat-inactivated serum has lower GIA activity. It does not preclude that there may be differences in the levels of malaria-specific IgM which has not been assessed. This is the main antibody isotype fixing complement and there may be differences in the distribution of malaria-specific IgM and IgG in the different age groups.

Conclusion
In conclusion, the present study reveals differential relationships between adaptive immunity, innate immunity (mainly the role of complement), and response to drug treatment as function of age of the symptomatic study participants. Anti-parasitic activity (GIA) significantly correlated with T 1/2 and K only in sera of younger symptomatic patients. This effect is dependent of intact (nonheat inactivated serum) indicating the importance of innate factors such as complement. These findings provide insight into improvement in effective use of ACT Fig. 3 Age is not a confounding factor in the entire patient population. Boxplot showing impact of age < 5 years (n = 46) and ≥ 5 years (n = 59) on GIA in sera from symptomatic patients Table 2 Correlation between parasitological response to drugs and pre-existing GIA activity a Stratification of study participants based on Slope half-life T1/2 17